Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 6/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18120321 | 0.88 | TLR2 (0.45) | TLR2EPHX2 | |
| SCHEMBL16476478 | 0.84 | MEN1 (0.40) | MEN1KMT2ATLR2EPHX2POLB | |
| SCHEMBL25664937 | 0.78 | ADRB2 (0.37) | MEN1KMT2ATLR2POLBADRB2 | |
| SCHEMBL14685800 | 0.75 | GLP1R (0.46) | EPHX2TSHRALDH1A1 | |
| SCHEMBL26346649 | 0.75 | MEN1 (0.31) | MEN1KMT2ATLR2 | |
| SCHEMBL18313748 | 0.74 | MEN1 (0.49) | MEN1KMT2ATLR2POLBADRB2 | |
| SCHEMBL24602601 | 0.73 | MEN1 (0.41) | MEN1KMT2ATLR2POLBADRB2 | |
| SCHEMBL16062708 | 0.73 | GLP1R (0.47) | MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL15697747 | 0.73 | MEN1 (0.42) | MEN1KMT2AEPHX2POLBTSHR | |
| SCHEMBL24602591 | 0.72 | MEN1 (0.44) | MEN1KMT2ATLR2POLBADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629101-B2 | Cholesterol derivatives of inhibitors of viral fusion | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2014-01-14 | — | — | US | disclosed |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | MSD ITALIA S.R.L. (IT) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305028-A1 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION | HDLBP, CETP, NPC1 | MEN1 2542/4885KMT2A 2568/4885TLR2 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.